Skip To Main Content
Sandjai Ramsoekh on Muck Rack

Sandjai Ramsoekh

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sandjai

Contact Sandjai, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial

|
By Artemiy Kovynev, Marcos F. Fondevila, Michiel C. Mommersteeg, Christian R Ramakers, Barbara A. Hutten, Bart J. Verwer, Marije S Vlug, Anne Vrieze, Maurice B. Bizino, Djuna L. Cahen, Robert C. Verdonk, Wouter De Jonge, Michail Doukas, Joanne Verheij, Ulrich Beuers, Geert D’Haens, Joost P. H. Drenth, Tamar Tchkonia, Bernd Schnabl, James Kirkland, Abraham S. Meijnikman, Mijra Koning, Eliza J. M. Ruhe, Teaco Kuiper, Maarten van den Berg, Annewieke van den Beld, Luuk Berk, Thomas Boerlage, Quinten J. J. Augustijn, Weena J. Chen, Sandjai Ramsoekh, Sanne M. M. Vermorgen, R. B. Takkenberg, Jacques J. G. Bergman
| Nature Verified
Abstract Cellular senescence plays an important role in hepatic inflammation and fibrosis1,2,3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH.
Open in Who Shared Issue with article?
See all 1 articles